Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
According to Celltrion, Inc.'s latest financial reports the company's current revenue (TTM) is $1.59 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
---|---|---|---|---|---|
2023 | $1.59 B | $739.59 M | $656.34 M | $499.26 M | $391.89 M |
2022 | $1.67 B | $755.53 M | $638.82 M | $458.11 M | $393.49 M |
2021 | $1.4 B | $809.01 M | $730.71 M | $549.67 M | $423.94 M |
2020 | $1.35 B | $751.85 M | $614.92 M | $480.78 M | $378.8 M |
2019 | $825.59 M | $463.47 M | $399.3 M | $279.5 M | $220.24 M |
2018 | $718.5 M | $403.05 M | $324.75 M | $220.68 M | $179.8 M |
2017 | $694.36 M | $510.54 M | $436.74 M | $353.42 M | $269.39 M |
2016 | $490.6 M | $290.16 M | $254.76 M | $167.78 M | $130.22 M |
2015 | $441.46 M | $269.85 M | $241.42 M | $119.33 M | $112.73 M |
2014 | $344.62 M | $249.58 M | $193.03 M | $109.09 M | $82.44 M |
2013 | $165.5 M | $115.24 M | $144.59 M | $84.62 M | $74.96 M |
2012 | $256.21 M | $187.5 M | $176.64 M | $137.23 M | $127.62 M |
2011 | $204.15 M | $165.92 M | $148.49 M | $134.17 M | $122.77 M |
2010 | $132.38 M | $103.54 M | $92.12 M | $80.37 M | $79.29 M |
2009 | $106.49 M | $68.74 M | $59.83 M | $48.58 M | $42.83 M |
2008 | $61.23 M | $34.79 M | $12.69 M | $12.89 M | $10.66 M |
2007 | $43.96 M | $6.75 M | $4.64 M | $195.52 K | $1.67 M |